We are a commercial stage medical device company focused on the development of innovative treatment options for the management of fluid overload in liver disease, malignant ascites and heart failure.
The alfapump®, is a fully implantable, programmable, wirelessly-charged, battery-powered system that is CE-marked for the treatment of refractory ascites due to liver cirrhosis and malignant ascites.
Over 750 alfapump® systems have been implanted. The alfapump® has been endorsed by key independent third parties in Europe and has received Breakthrough Device status from the US FDA.
We have leveraged our alfapump® technology experience and are developing alfapump® DSR, a novel and proprietary approach to the treatment of volume overload in patients suffering from heart failure.
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.